Skip to main content
ALZN
NASDAQ Life Sciences

FDA Rejects AL001 Bipolar Trial Design; MGH Terminates BD Study Work

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.11
Mkt Cap
$5.453M
52W Low
$0.84
52W High
$2.56
52W Position info
32% above low
Off High info
57% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ALZN sits 32% above its 52-week low of $0.84 on light trading volume (0.3× avg).

Summary

The FDA rejected Alzamend's bipolar-disorder trial design as inadequate for approval, and on November 11, 2026 MGH terminated the related study work. The company now plans a Type B meeting to propose skipping Phase II for a Phase III trial, with FDA feedback not expected until the end of Q2 2027.


Key Events · Product Development and Regulatory · ALZN

  • FDA Rejects Bipolar Trial Design

    In written feedback dated October 15, 2026, the FDA said the proposed trials did not appear designed as adequate and well-controlled studies capable of providing substantial evidence of effectiveness.

  • MGH Terminates BD Study Work

    After the company paused the BD Clinical Trial on October 21, 2026, MGH delivered written notice on November 11, 2026 terminating the BD statement of work and reassigning staff; Alzamend will receive a refund of approximately $25,000 in unused funds.

  • Phase III Pivot Proposed

    Alzamend intends to request a Type B meeting to propose ceasing Phase II trials of AL001 and moving directly into a Phase III efficacy and safety trial in bipolar disorder supporting an NDA.

  • FDA Feedback Slips to Mid-2027

    The company is preparing a briefing package and currently anticipates receiving FDA feedback by the end of the second quarter of 2027.


Analysis · ALZN · Life Sciences

Alzamend's bipolar-disorder program has lost its regulatory footing: the FDA said the proposed trial design would not yield the adequate and well-controlled evidence needed for approval, and Massachusetts General Hospital has now walked away from the study entirely. That leaves no active bipolar trial, a plan to leap straight to a Phase III that regulators have not yet agreed to, and a timeline pushing any FDA feedback to the end of the second quarter of 2027. For a company already carrying going-concern doubt, the nearest source of clinical news is gone and the path to an NDA stretches by well over a year, leaving only the December 2026 healthy-volunteer results as a near-term readout.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALZN was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.84 to $2.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALZN - Latest Insights

ALZN
Nov 10, 2026, 4:30 PM EST
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $1.11 info
Change: -$0.240 (-18%) info
Market Cap: $5.453M info
ALZN
Sep 10, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.70
Real-time Price: $1.11 info
Change: -$0.590 (-35%) info
Market Cap: $5.453M info
ALZN
Aug 28, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.66
Real-time Price: $1.11 info
Change: -$0.550 (-33%) info
Market Cap: $5.453M info
ALZN
Aug 21, 2026, 4:30 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.11 info
Change: -$0.390 (-26%) info
Market Cap: $5.453M info
ALZN
Aug 03, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.35
Real-time Price: $1.11 info
Change: -$0.240 (-18%) info
Market Cap: $5.453M info